7H-Pyrrolo[2,3-d]pyrimidine is used as an organic synthesis or pharmaceutical intermediate. Its pyrrolo[2,3-d]pyrimidines are important parent heterocyclic compounds and are synthetic raw materials for the preparation of anti-rheumatoid arthritis and anti-tumour drugs.
4-Chloro-7H-pyrrolo[2,3-d]pyrimidine (compound 1001) (130 mg, 0.847 mmol) was used as a raw material and dissolved in 3 mL of methanol. The hydrogenation reaction was carried out by adding 10% Pd-C catalyst under hydrogen atmosphere at 1 atmosphere for 16 hours. Upon completion of the reaction, the reaction solution was concentrated to dryness to afford 7H-pyrrolo[2,3-d]pyrimidine (Compound 1002) in 100 mg yield and 98% yield. The product was characterized by 1H-NMR (CD3OD): δ 9.4 (s, 1H); 9.1 (s, 1H); 7.9 (s, 1H); 7.1 (s, 1H).
[1] Patent: WO2007/41130, 2007, A2. Location in patent: Page/Page column 40; Sheet 1/9
[2] Patent: US2008/9514, 2008, A1. Location in patent: Page/Page column 26-27
[3] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 21, p. 5247 - 5250
[4] European Journal of Medicinal Chemistry, 2008, vol. 43, # 6, p. 1248 - 1260
[5] Patent: WO2012/2568, 2012, A1. Location in patent: Page/Page column 37